Comparison of median progression-free survival (mPFS) and median overall survival (mOS) in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) based on the use of thoracic radiotherapy (TRT) in association with chemotherapy (CT), prophylactic cranial irradiation (PCI) and disease localisation at diagnosis
| mPFS months (95% CI) | p-value | mOS months (95% CI) | p-value | |
| SCLC | ||||
| First-line treatment | 0.0001 | 0.0001 | ||
| CT-TRT | 9.5 (4.6–14.5) | 34.3 (10.7–57.9) | ||
| CT | 4.6 (4.1–5.1) | 8.1 (6.6–9.6) | ||
| PCI | 0.0001 | 0.001 | ||
| Yes | 8.6 (6.2–11) | 34 (10.6–57.4) | ||
| No | 4.6 (4.1–5.1) | 8.4 (4.9–11.9) | ||
| Stage | 0.02 | |||
| III | 9.2 (7.7–10.7) | 18.4 (14.9–21.9) | ||
| IV | 5.4 (3.8–7) | 9.2 (6–12) | ||
| Site of disease | 0.06 | 0.06 | ||
| Thoracic | 7.8 (4.3–11.3) | 15.4 (10.7–20.1) | ||
| Extrathoracic | 4.9 (2.3–7.5) | 8.4 (6.1–10.7 | ||
| LCNEC | ||||
| First-line treatment | 0.02 | 0.04 | ||
| CT-TRT | 12.5 (11.1–13.9) | 28.3 (0–60.7) | ||
| CT | 5 (3.8–6.2) | 5 (2.7–7.3) | ||
| PCI | 0.09 | 0.05 | ||
| Yes | 20.5 (0–46.7) | 33.4 (8–53.4) | ||
| No | 6.4 (3.4–9.4) | 8.6 (3.4–13.8) | ||
| Stage | 0.004 | |||
| III | 12.5 (11–14) | 28.3 (0–59.4) | ||
| IV | 4.5 (2.6–6.4) | 4.9 (2.2–7.6) | ||
| Site of disease | 0.02 | 0.04 | ||
| Thoracic | 10.8 (8.8–12.8) | 13.3 (0–33) | ||
| Extrathoracic | 5.1 (2.7–7.5) | 8 (3.5–12.5) |